The low basal expression of APOL1 in tumor cells may already be sufficient to fulfill its oncogenic functions, while the downregulation of APOL1 in tumor cells could be a strategy employed by cancer cells to achieve immune evasion. This evidence concerns the gene APOL1 and cancer.